Anti-TNFalpha: a new dimension in the pharmacotherapy of the spondyloarthropathies !?
作者信息
Braun J, Sieper J
机构信息
Rheumatology Klinikum B Franklin Free University Berlin, Germany.
出版信息
Ann Rheum Dis. 2000 Jun;59(6):404-7. doi: 10.1136/ard.59.6.404.
Abstract
摘要
相似文献
1
Anti-TNFalpha: a new dimension in the pharmacotherapy of the spondyloarthropathies !?抗肿瘤坏死因子α：脊柱关节病药物治疗的新维度！？
Ann Rheum Dis. 2000 Jun;59(6):404-7. doi: 10.1136/ard.59.6.404.
2
New treatment options in spondyloarthropathies: increasing evidence for significant efficacy of anti-tumor necrosis factor therapy.脊柱关节病的新治疗选择：抗肿瘤坏死因子治疗显著疗效的证据不断增加。
Curr Opin Rheumatol. 2001 Jul;13(4):245-9. doi: 10.1097/00002281-200107000-00001.
3
Recommendations of the French Society for Rheumatology regarding TNFalpha antagonist therapy in patients with ankylosing spondylitis or psoriatic arthritis: 2007 update.法国风湿病学会关于强直性脊柱炎或银屑病关节炎患者肿瘤坏死因子α拮抗剂治疗的建议：2007年更新版
Joint Bone Spine. 2007 Dec;74(6):638-46. doi: 10.1016/j.jbspin.2007.10.003. Epub 2007 Nov 8.
4
Infliximab treatment for rheumatic disease: clinical and radiological efficacy.英夫利昔单抗治疗风湿性疾病：临床及影像学疗效
Ann Rheum Dis. 2002 Nov;61 Suppl 2(Suppl 2):ii67-9. doi: 10.1136/ard.61.suppl_2.ii67.
5
Switching tumour necrosis factor alpha antagonists in patients with ankylosing spondylitis and psoriatic arthritis: an observational study over a 5-year period.强直性脊柱炎和银屑病关节炎患者转换肿瘤坏死因子α拮抗剂：一项为期5年的观察性研究。
Ann Rheum Dis. 2007 Oct;66(10):1393-7. doi: 10.1136/ard.2007.073569. Epub 2007 Jul 5.
6
[Anti-TNF-alpha treatment and spondyloarthropathies].[抗肿瘤坏死因子-α治疗与脊柱关节病]
Harefuah. 2002 Nov;141(11):965-8, 1010.
7
Efficacy of infliximab (Remicade) in the treatment of spondyloarthropathies. two case reports.英夫利昔单抗（类克）治疗脊柱关节病的疗效：两例病例报告
Joint Bone Spine. 2001 Dec;68(6):525-7. doi: 10.1016/s1297-319x(01)00320-7.
8
Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy.阿达木单抗治疗有抗肿瘤坏死因子治疗史的强直性脊柱炎或银屑病关节炎患者的有效性和安全性。
Arthritis Res Ther. 2010;12(3):R117. doi: 10.1186/ar3054. Epub 2010 Jun 16.
9
Costs of tumor necrosis factor blockers per treated patient using real-world drug data in a managed care population.在管理式医疗人群中使用真实世界药物数据计算每名接受治疗患者的肿瘤坏死因子阻滞剂成本。
J Manag Care Pharm. 2013 Oct;19(8):621-30. doi: 10.18553/jmcp.2013.19.8.621.
10
Biologic therapies in the spondyloarthritis: new opportunities, new challenges.脊柱关节炎的生物治疗：新机遇，新挑战。
Curr Opin Rheumatol. 2003 Jul;15(4):394-407. doi: 10.1097/00002281-200307000-00005.
引用本文的文献
1
Axial Spondyloarthritis: an overview of the disease.轴性脊柱关节炎：疾病概述
Rheumatol Int. 2024 Sep;44(9):1607-1619. doi: 10.1007/s00296-024-05601-9. Epub 2024 Apr 30.
2
Correlation of serum MMP3 and other biomarkers with clinical outcomes in patients with ankylosing spondylitis: a pilot study.血清基质金属蛋白酶3及其他生物标志物与强直性脊柱炎患者临床结局的相关性：一项初步研究。
Clin Rheumatol. 2017 Aug;36(8):1819-1826. doi: 10.1007/s10067-017-3624-7. Epub 2017 Apr 22.
3
[Biologics in the early treatment of ankylosing spondylitis and related forms of spondyloarthritis].生物制剂在强直性脊柱炎及相关脊柱关节炎早期治疗中的应用
Wien Med Wochenschr. 2008;158(7-8):200-5. doi: 10.1007/s10354-008-0522-2.
4
Treatment of spondyloarthropathies with antibodies against tumour necrosis factor alpha: first clinical and laboratory experiences.使用抗肿瘤坏死因子α抗体治疗脊柱关节炎：首批临床和实验室经验。
Ann Rheum Dis. 2000 Nov;59 Suppl 1(Suppl 1):i85-9. doi: 10.1136/ard.59.suppl_1.i85.
本文引用的文献
1
Treatments used by patients with ankylosing spondylitis comparison with the treatment preferences of rheumatologists.
J Clin Rheumatol. 1999 Feb;5(1):1-8. doi: 10.1097/00124743-199902000-00001.
2
Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study.三次输注肿瘤坏死因子α嵌合单克隆抗体（英夫利昔单抗）负荷剂量方案对脊柱关节病的影响：一项开放性初步研究。
Ann Rheum Dis. 2000 Jun;59(6):428-33. doi: 10.1136/ard.59.6.428.
3
4
Health-related quality of life in ankylosing spondylitis: a survey of 175 patients.强直性脊柱炎患者的健康相关生活质量：175例患者的调查
Arthritis Care Res. 1999 Aug;12(4):247-55.
5
Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group.英夫利昔单抗（嵌合型抗肿瘤坏死因子α单克隆抗体）与安慰剂用于接受甲氨蝶呤联合治疗的类风湿关节炎患者：一项随机III期试验。ATTRACT研究组。
Lancet. 1999 Dec 4;354(9194):1932-9. doi: 10.1016/s0140-6736(99)05246-0.
6
Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs.与非甾体抗炎药相比，罗非昔布对上消化道的不良影响。
JAMA. 1999 Nov 24;282(20):1929-33. doi: 10.1001/jama.282.20.1929.
7
Immunomodulation by thalidomide and thalidomide analogues.沙利度胺及其类似物的免疫调节作用
Ann Rheum Dis. 1999 Nov;58 Suppl 1(Suppl 1):I107-13. doi: 10.1136/ard.58.2008.i107.
8
Long-term follow-up of the changes in circulating cytokines, soluble cytokine receptors, and white blood cell subset counts in patients with rheumatoid arthritis (RA) after monoclonal anti-TNF alpha antibody therapy.类风湿关节炎（RA）患者接受单克隆抗TNFα抗体治疗后循环细胞因子、可溶性细胞因子受体及白细胞亚群计数变化的长期随访
J Clin Immunol. 1999 Sep;19(5):305-13. doi: 10.1023/a:1020543625282.
9
Defining disease activity in ankylosing spondylitis: is a combination of variables (Bath Ankylosing Spondylitis Disease Activity Index) an appropriate instrument?定义强直性脊柱炎的疾病活动度：变量组合（巴斯强直性脊柱炎疾病活动指数）是否为合适的工具？
Rheumatology (Oxford). 1999 Sep;38(9):878-82. doi: 10.1093/rheumatology/38.9.878.
Zotero 插件